Abstract Purpose: To investigate the antibacterial and α-glucosidase inhibitory activities of hydrazone derivatives (8a-h) of ethyl isonipecotate.
INTRODUCTION
The labile lone pair of nitrogens in hydrazones is known to play an active role in the bioactivity and chemical reactivity of this class of compounds [1, 2] . These compounds have been shown to have anti-tuberculosis [3] , antimicrobial [4] , antimycotic [5] and antihypertensive activities [6] .
Furthermore, industrial chemistry has found many applications for hydrazones [7] [8] [9] . α-Glucosidase (EC 3.2.1.20) is an enzyme that acts on 1,4-alpha bonds [10, 11] .
The cleavage of carbohydrates is delayed by α-glucosidase inhibitors (AGI) in the small intestine [12, 13] . In search of bioactive compounds, an attempt was made to synthesize some new hydrazones bearing a sulfamoyl moiety.
EXPERIMENTAL
All chemical reagents were from Merck, Sigma Aldrich and Alfa Aesar and purchased through local suppliers, and they were used without further purification. Purity of the synthesized compounds was assured by thin layer chromatography (TLC); the plates were developed with n-hexane and ethyl acetate solvent systems and visualized under UV at 254 nm and also by spraying with ceric sulfate solution.
The melting points of all synthesized compounds were determined using open capillary tubes on a Griffin and George apparatus. IR spectra were recorded using the potassium bromide pellet method on a Jasco-320-A spectrophotometer with wave number in cm -1 . 1 H-NMR spectra were recorded in CDCl 3 on a Bruker spectrometer operating at 400 MHz. Chemical shift values are reported in ppm (δ) units taking TMS as reference and the coupling constants (J) are in Hz. Mass spectra (EIMS) were recorded on a JMS-HX-110 spectrometer.
Procedure for synthesis of sulfonamide (3) in aqueous medium
Ethyl isonipecotate (6.49 mmol; 1 mL, 2) was added to a 100-mL round-bottom flask containing 15 mL basic aqueous medium prepared by addition of aqueous Na 2 CO 3 with pH adjusted to 8-9. Next, 3,5-dichloro-2-hydroxybenzenesulfonylchloride (6.49 mmol; 1.698 g, 1) was gradually added to the reaction flask over 5-10 min. The reaction mixture was stirred for 6-8 h with pH maintained at 8-9 at ambient temperature. The completion of the reaction was checked by TLC until confirmed by a single spot. Product 3 was collected by acidifying the reaction mixture with dilute HCl to bring the pH to 5-7. The synthesized product was collected by filtration, washed with distilled water and dried for next use.
Procedure for synthesis of O-alkyl derivative (5)
Compound 3 (0.5249 mmol, 0.2 g) was dissolved in DMF (5 mL) in a 100-mL round-bottom flask. Solid KOH (0.5249 mmol, 0.0293 g) was added to activate the O-substitution. Ethyl iodide (0.5249 mmol; 42.2 µL, 4) was then added, and the mixture was stirred for 2-3 h at 60 ºC. Completion of the reaction was confirmed by TLC showing a single spot. Chilled distilled water was used to collect the precipitates of pure product 5. Precipitates were filtered, washed with distilled water and dried.
Procedure for synthesis of carbohydrazide (6)
Compound 5 (1.467 mmol, 0.6 g) was dissolved in MeOH (5-10 mL) in a 100-mL round-bottom flask and stirred for 2-5 min. Hydrazine hydrate (1.467 mmol) was then added and the reaction mixture was refluxed for 6 h. There was a color change in the reaction mixture from orangeyellow to grey as the reaction proceeded toward completion. The progress of the reaction was followed by TLC. After reaction completion, the mixture was quenched with cold distilled water and the precipitates of 6 were filtered, washed with distilled water and dried for further use.
General procedure for synthesis of various hydrazone derivatives (8a-h)
A methanolic solution of compound 6 (0.2523 mmol, 0.1 g) was placed in a 50-mL roundbottom flask and stirred at room temperature. Aromatic aldehydes (7a-h) were introduced in equimolar ratios to produce hydrazone derivatives. The reaction duration for different aldehydes varied 2-3 h. Reaction completion was confirmed by TLC, and distilled water was added to the mixture to precipitate the compounds synthesized, 8a-h, which were filtered, washed with distilled water and dried.
Evaluation of antibacterial activity
The broth microdilution method was employed to test for antibacterial activity [14] . The solutions of synthesized compounds were mixed with bacterial strains and change in absorbance before and after incubation was determined.
α-Glucosidase assay
α-Glucosidase inhibitory activity was determined as previously described, with slight modification [15] . Enzyme activity was based on the difference in absorbance of the mixture of synthesized compounds and enzyme before and after incubation with substrate.
Molecular docking study
The crystallographic structure of Saccharomyces cerevisiae isomaltase (PDB code 3AJ7; resolution 1.30 Å) showing 72.4 % sequence identity with the target was selected as a template. The 3D structure of α-glucosidase for Saccharomyces cerevisiae was predicted using the Molecular Operating Environment (MOE 2010.11) software package. MOE docking program was used to analyze the binding modes of the ligands with the protein molecule. The best conformations were analyzed for hydrogen bonding and π-π interactions [16] [17] [18] .
Statistical analysis
The results are presented as mean ± SEM (n = 3) and were analyzed by Microsoft Excel 2010. The results for 50 % inhibitory concentration (IC 50 ) and minimum inhibitory concentration (MIC) were obtained at different dilutions (5 -30 µg/well) and analyzed by EZ-Fit software (Perrella Scientific Inc., Amherst, USA).
RESULTS

1-(3,5-Dichloro-2-ethoxybenzenesulfonyl)-N′-(arylidene)piperidin-4-carbohydrazides,
8a-h, were prepared according to the protocol described in Scheme 1. The synthesized compounds exhibited substantial α-glucosidase inhibitory activity and antibacterial activity. • 
1-(3,5-Dichloro-2-ethoxyphenylsulfonyl)-N′-(2-hydroxybenzylidene)piperidin-4-carbohydrazide (8e)
Off white powder; Yield: 99 %; IR (KBr): 
1-(3,5-Dichloro-2-ethoxyphenylsulfonyl)-N′-(4-dimethylamino)benzylidene) piperidin-4-carbohydrazide (8f)
Off white powder; Yield: 100 %; IR (KBr): υ max : 3128 (Ar-H), 3000 (C-H), 1665 (C=N), 1597 (Aromatic C=C), 1405 (-SO 2 ), 1102 (C-O-C); • 
1-(3,5-Dichloro-2-ethoxyphenylsulfonyl)-N′-(2-nitrobenzylidene)piperidine-4-carbohydrazide (8h)
Light
Biological studies
The results for in vitro antibacterial activity against Salmonella typhi, Escherichia coli, Pseudomonas aeruginosa, Bacillus subtilis and Staphylococcus aureus are presented in Table 1 and those for in vitro α-glucosidase inhibitory activity are presented in Table 2 .
Molecular docking
With regard to hydroxyl-containing compounds (8b and 8e), the docking conformation of 8e (ortho analogue) showed good interaction network as well as good docking score compared (Figure 2b ). In case of dimethoxy substituted compound 8g, the docking conformation showed moderate interaction pattern.
The two methoxy groups present at the meta and para position at adjacent carbon atoms displayed poor interaction, which might have been due to higher steric strain. The docking conformation of compound 8g showed two arene-arene interactions with Phe 157 and His 239 residues of the enzyme (Figure 2c ).
DISCUSSION
The synthesis of compound 8a yielded a white powder. Its molecular formula, were assigned to five protons of the ethoxy group, ortho to sulfonyl group. A chemical shift value at δ 3.81 was assigned to singlet of the methoxy group attached to one of the benzene rings. The singlet appearing at δ 8.38 (s, 1H, H-7''), due to a downfield shift, was attributed to a proton of the imine group. The structure of 8a was substantiated and designated 1-[(3,5-dichloro-2-ethoxyphenyl)sulfonyl]-N′-(4-methoxybenzylidene)piperidin-4-carbohyrazide.
The structure of the other compounds was likewise established.
The screening of all these synthesized compounds against Gram-positive and -negative bacterial strains showed potent antibacterial activity in all but a few. Compounds 8e and 8c exhibited good inhibition percentage and MIC values against all bacterial strains, possibly due to the presence of a 2-hydroxyphenyl and 3-nitrophenyl group, respectively, in comparison to ciprofloxacin, taken as reference standard. Compounds 8a, 8b, 8d, 8f, 8g and 8h demonstrated good to moderate activity against both Gram-positive and -negative bacterial strains. S. typhi was best inhibited by molecule 3 (ethyl ester) with a MIC of 7.99 ± 0.86 µM and 8e (bearing 2-hydroxyphenyl group) with a MIC of 8.00 ± 0.54 µM relative to 7.12 ± 0.21 µM for ciprofloxacin. Against E. coli, molecule 6 (carbohydrazide) with a MIC of 8.05 ± 0.52 µM and 8f (bearing a 4-(dimethylamino)phenyl group) with a MIC of 8.21 ± 0.83 µM were the most effective in comparison to 7.05 ± 0.28 µM for the reference. The synthesized compounds showed relatively moderate activity against B. subtilis with the lowest MIC for 8c (bearing a 3-nitrophenyl group) at 8.56 ± 0.63 µM as compared to 7.65 ± 0.48 µM for the standard. The moderate to excellent activity against Staphylococcus aureus rendered 3 (ethyl ester) and 8c (bearing a 3-nitrophenyl group) the best ones with MIC values of 8.43 ± 0.79 and 8.86 ± 0.29 µM in comparison to 7.89 ± 0.27 µM.
Similarly, evaluation of α-glucosidase inhibitory activity of all synthesized compounds showed moderate activity except 8a, 8c and 8h, the inactive ones. Good activity was shown by 8e and 8d with respective IC 50 values of 40.62 ± 0.07 and 48.64 ± 0.08 µM in comparison to 38.25 ± 0.12 µM for acarbose, the positive control. The activity of 8e and 8d was probably due to the presence of a hydroxyl and chloro group in these compounds. Compounds 8b, 5 and 8f were less active, and 3, 6 and 8g had very low poorly active. However, 8a and 8b showed outstanding activity and could be further evaluated for the treatment of type-2 diabetes.
CONCLUSION
The biological activity data obtained demonstrate that the target compounds are significant inhibitors of bacterial growth and α-glucosidase activity. On the basis of the aforementioned results, these newly synthesized compounds may be further developed for the treatment of type-2 diabetes and bacterial infections.
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